BioView, Kindstar Ink Deal for Lung Cancer Test | GenomeWeb

NEW YORK (GenomeWeb News) – BioView and Kindstar Global this week announced an agreement granting Kindstar an exclusive license to validate and implement BioView's test for the early detection of lung cancer.

BioView's test is based on fluorescent in situ hybridization technology. Under the deal, Kindstar will purchase equipment and kits from BioView and will exclusively perform the test in China, Macau, Hong Kong, and Taiwan.

Beijing-based Kindstar has already successfully carried out a pilot study using BioView's assay, the partners said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

BMJ study says that about half of former hematology-oncology regulators now work for industry.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.